Aldeyra Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies designed to treat immune-mediated diseases. The company's proprietary platform targets reactive aldehyde species (RASP), which are pro-inflammatory mediators upstream of cytokine release and inflammation. Aldeyra's lead product candidate is reproxalap, a first-in-class, topically administered RASP modulator in late-stage development for dry eye disease and allergic conjunctivitis. Other pipeline assets include ADX-2191 (intravitreal methotrexate) for primary vitreoretinal lymphoma and retinitis pigmentosa, as well as next-generation RASP modulators ADX-248 and ADX-246.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Resolving the regulatory path for lead candidate reproxalap following the March 2026 Complete Response Letter. The company is focusing on exploring trial failures and identifying specific patient populations or conditions where the drug is effective, rather than initiating new clinical trials.
Expected impact: Aims to secure FDA approval for reproxalap in dry eye disease, unlocking commercialization and partnership milestones.
Advancing ADX-2191 (intravitreal methotrexate) for rare retinal diseases, including primary vitreoretinal lymphoma (PVRL) and retinitis pigmentosa. The program is supported by FDA Fast Track and Orphan Drug designations, as well as EMA Orphan Designation.
Expected impact: Establishes a high-value pipeline in orphan ophthalmic indications with significant unmet medical needs.
Transitioning clinical focus from ADX-629 to more potent, next-generation RASP modulators ADX-248 (oral) and ADX-246 (intravitreal) for systemic and retinal immune-mediated diseases.
Expected impact: Expands the company's proprietary platform into systemic inflammatory and retinal degenerative markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Aldeyra with the commercialization infrastructure, marketing reach, and financial backing of a global pharmaceutical leader, significantly mitigating commercial launch risks for reproxalap.
Terms: AbbVie holds an option to acquire a co-exclusive U.S. license and exclusive ex-U.S. license for reproxalap. Upon exercise, AbbVie pays a $100 million upfront cash payment (less $6 million in prior option fees). Aldeyra is eligible for up to $300 million in regulatory and commercial milestones (including $100 million upon FDA approval). U.S. profits and losses are split 60% to AbbVie and 40% to Aldeyra, with tiered royalties for ex-U.S. sales.